Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505^[1][2].

when preincubated with rabbit platelets, the potency of antagonizing PAF induced aggregation increased markedly when preincubation time with Modipafant was increased from 2 min (IC₅₀=5.6 nM) to 60 min (IC₅₀=0.34 nM)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

605.09

C₃₄H₂₉ClN₆O₃

122957-06-6

Room temperature in continental US; may vary elsewhere.

• [1]. Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995;151(5):1331-1335.  [Content Brief]

  [2]. Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996;26(9):963-975.  [Content Brief]